Johnson & Johnson announced results for the “gold standard endpoint in cancer treatment” of overall survival from the Phase 3 MARIPOSA ...

Johnson & Johnson announced that new data from its oncology pipeline will be presented at the 2025 European Lung Cancer Congress, including ...

The Business Research Company's Rybrevant Global market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early ...

(RTTNews) - Johnson & Johnson (JNJ) Thursday reported positive data from the Phase 3 MARIPOSA study evaluating rybrevant plus lazcluze versus osimertinib in the first-line treatment of patients ...

AstraZeneca's EGFR inhibitor Tagrisso has become the go-to therapy for EGFR-mutated non-small cell lung cancer (NSCLC), but now has competition from Johnson & Johnson's Rybrevant and Lazcluze ...

The study showed that the combination of RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib) significantly improved survival outcomes compared to the current standard treatment ...

Johnson & Johnson's hopes of quickly building its new cancer drug Rybrevant into a $5 billion product have been undermined by an FDA decision. The US regulator has turned down J&J's marketing ...

But that status has recently come under attack from Johnson & Johnson’s combination of Rybrevant and Lazcluze. Rybrevant, an EGFRxMET bispecific antibody, is also approved in combination with ...

The best free logo maker is a great choice for those who need to create logos for their businesses without paying for subscriptions or licenses. I'll cut to the chase: for a free logo designer ...

The best logo maker is an essential design tool for anyone looking to differentiate their brand online. My round-up here offers apps ideal for designers and non-designers who need to help their ...

With a powerful logo and striking color, the brand captures and amplifies the spirit and energy of the WTA, bringing the drama of women's tennis to life like never before. Honoring the WTA's ...